To identify well‐studied treatment approaches with consistent and robust positive effects in tauopathy mouse models, we examined the frequency with which each treatment strategy was tested against the two most frequently measured endpoints – pathological tau and cognitive deficits – and the proportion of evaluations that elicited a therapeutic effect on each endpoint (Figure 7). This evidence concerns the gene MAPT and tauopathy.